Table 1 Patients’ clinical and demographic characteristics
ID | Gender | Age | Histology (WHO) | Ann Arbor classification at onset | Treatment | Post-therapy residual mass (cm)* |
|---|---|---|---|---|---|---|
1 | F | 36 | HL | 2B | Chemo + RT | 5 × 3 |
2 | F | 46 | HL | 2B | Chemo + RT | 2 × 1.7 |
3 | M | 45 | HL | 2A | Chemo + RT | 3 × 1 |
4 | M | 54 | HL | 2B | Chemo + RT | 7 × 4 |
5 | F | 33 | PMBL | 2B | Chemo + RT | 4 × 1.5 |
6 | M | 36 | HL | 2A | Chemo + RT | 3.5 × 2.6 |
7 | F | 27 | HL | 2B | Chemo + RT | 4 × 3 |
8 | M | 25 | HL | 2B | Chemo + RT | 7.7 × 5.8 |
9 | F | 30 | HL | 3B | Chemo | 5 × 2.8 |
10 | F | 36 | HL | 2B | Chemo + RT | 2 × 2 |
11 | F | 37 | PMBL | 2B | Chemo + RT | 5 × 9 |
12 | F | 37 | PMBL | 2B | Chemo + RT | 4 × 5 |
13 | F | 43 | PMBL | 2B | Chemo + RT | 2 × 0.8 |
14 | F | 30 | HL | 2B | Chemo + RT | 5 × 4 |
15 | F | 47 | PMBL | 3B | Chemo + RT | 2 × 1.4 |
16 | F | 28 | HL | 2A | Chemo | 1.4 × 1.7 |
17 | M | 38 | HL | 2B | Chemo + RT | 1.7 × 3 |
18 | F | 29 | PMBL | 4B (lung) | Chemo + RT | 1 × 1 |
19 | F | 25 | HL | 4B (liver) | Chemo | 3.4 × 3 |
20 | M | 30 | PMBL | 4B (lung, liver) | Chemo | 5 × 2 |
21 | M | 45 | DLBCLnos | 3B | Chemo | 12 × 3 |